Search results
9 mar 2021 · The first batch of COVID‑19 vaccines from the COVAX Facility that arrived in Indonesia is the AstraZeneca vaccine that was produced in South Korea and shipped via AstraZeneca's hub in Amsterdam, Netherlands.
6 mar 2021 · Vaccines to prevent COVID-19 infection are crucial for an effective global pandemic response. In The Lancet, Merryn Voysey and colleagues 1 report the updated primary efficacy results for the Oxford–AstraZeneca ChAdOx1 nCoV-19 (AZD1222) vaccine from three single-blind, randomised controlled trials in the UK and Brazil and one double-blind ...
3 lut 2021 · The primary analysis of the Phase III clinical trials from the UK, Brazil and South Africa, published as a preprint in The Lancet confirmed COVID-19 Vaccine AstraZeneca is safe and effective at preventing COVID-19, with no severe cases and no hospitalisations, more than 22 days after the first dose. Results demonstrated vaccine efficacy of 76% ...
COVID-19 vaccination certificate issued by the Indonesian government for the second dose vaccination. On 1 August, 3.5 million doses of the Moderna vaccine from the United States arrived in Indonesia. [64] On 2 August, 620,000 doses of the Oxford–AstraZeneca vaccine arrived in Indonesia.
Between 8 December 2020 and 15 February 2021, 1,137,775 participants were vaccinated in the study, 490,000 of whom were given the Oxford–AstraZeneca vaccine. The first dose of the Oxford–AstraZeneca vaccine was associated with a vaccine effect of 94% for COVID-19-related hospitalisation at 28–34 days post-vaccination.
9 sty 2021 · Further trials to substantiate the unexpected findings here and investigation of efficacy in older adults are now needed. When faced with vaccine choices, National Immunization Technical Advisory Groups will have to consider all factors and decide which vaccine is right for their setting.
3 sty 2022 · The UK's Medicines and Healthcare Products Regulatory Agency (MHRA) gave emergency use authorisation to three vaccines against COVID-19 between December 2020 and January 2021, namely the Pfizer/BioNTech BNT162b2 mRNA, Oxford/AstraZeneca ChAdOx1 nCoV-19 adenoviral AZD1222; and Moderna mRNA-1273 vaccines.
